Toward peptide-based inhibitors as therapies for Parkinson's disease

被引：6

作者：

Mason, Jody M. ^{[1
]}

Fairlie, David P. ^{[2
]}

机构：

[1] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England

[2] Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld, Australia

来源：

FUTURE MEDICINAL CHEMISTRY | 2015年 / 7卷 / 16期

基金：

英国工程与自然科学研究理事会;

关键词：

alpha-synuclein; amyloid; drug design; mimetics; Parkinson's disease; peptides; ALPHA-SYNUCLEIN AGGREGATION; ALZHEIMERS; MUTATIONS; FIBRILS; DESIGN;

D O I：

10.4155/fmc.15.139

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

引用

页码：2103 / 2105

页数：3

共 23 条

[1]

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation [J].

Bartels, Tim ;

Choi, Joanna G. ;

Selkoe, Dennis J. .

NATURE, 2011, 477 (7362) :107-U123

[2]

Intracellular Screening of a Peptide Library to Derive a Potent Peptide Inhibitor of α-Synuclein Aggregation [J].

Cheruvara, Harish ;

Allen-Baume, Victoria L. ;

Kad, Neil M. ;

Mason, Jody M. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (12) :7426-7435

[3]

Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses [J].

Connelly, Stephen ;

Choi, Sungwook ;

Johnson, Steven M. ;

Kelly, Jeffery W. ;

Wilson, Ian A. .

CURRENT OPINION IN STRUCTURAL BIOLOGY, 2010, 20 (01) :54-62

[4]

Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid [J].

Conway, KA ;

Harper, JD ;

Lansbury, PT .

BIOCHEMISTRY, 2000, 39 (10) :2552-2563

[5]

The Future of Peptide-based Drugs [J].

Craik, David J. ;

Fairlie, David P. ;

Liras, Spiros ;

Price, David .

CHEMICAL BIOLOGY & DRUG DESIGN, 2013, 81 (01) :136-147

[6]

Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation [J].

Dettmer, Ulf ;

Newman, Andrew J. ;

Soldner, Frank ;

Luth, Eric S. ;

Kim, Nora C. ;

von Saucken, Victoria E. ;

Sanderson, John B. ;

Jaenisch, Rudolf ;

Bartels, Tim ;

Selkoe, Dennis .

NATURE COMMUNICATIONS, 2015, 6

[7]

A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders [J].

El-Agnaf, OMA ;

Paleologou, KE ;

Greer, B ;

Abogrein, AM ;

King, JE ;

Salem, SA ;

Fullwood, NJ ;

Benson, FE ;

Hewitt, R ;

Ford, KJ ;

Martin, FL ;

Harriot, P ;

Cookson, MR ;

Allsop, D .

FASEB JOURNAL, 2004, 18 (09) :1315-+

[8]

The Parkinson's Disease-Associated H50Q Mutation Accelerates α-Synuclein Aggregation in Vitro [J].

Ghosh, Dhiman ;

Mondal, Mrityunjoy ;

Mohite, Ganesh M. ;

Singh, Pradeep K. ;

Ranjan, Priyatosh ;

Anoop, A. ;

Ghosh, Saikat ;

Jha, Narendra Nath ;

Kumar, Ashutosh ;

Maji, Samir K. .

BIOCHEMISTRY, 2013, 52 (40) :6925-6927

[9]

A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly [J].

Giasson, BI ;

Murray, IVJ ;

Trojanowski, JQ ;

Lee, VMY .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (04) :2380-2386

[10]

The E46K mutation in α-synuclein increases amyloid fibril formation [J].

Greenbaum, EA ;

Graves, CL ;

Mishizen-Eberz, AJ ;

Lupoli, MA ;

Lynch, DR ;

Englander, SW ;

Axelsen, PH ;

Giasson, BI .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (09) :7800-7807

← 1 2 3 →